First Fertility PGS Center Limited introduces fertility services tailored for Indian patients in Thailand’s growing medical tourism sector.

BANGKOK, May 27, 2025 — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a leading Asian fertility services provider, announced today that its subsidiary, First Fertility PGS Center Limited (“First Fertility”), is strategically expanding to cater to the Indian medical tourism market for fertility treatments.

This move allows NewGen to benefit from Thailand’s expanding fertility tourism sector, a popular choice for international patients seeking advanced reproductive care. According to ResearchAndMarkets, the global fertility tourism market, valued at US$709 million in 2023, is expected to reach approximately US$13.08 billion by 2034, with a compound annual growth rate of 30.34%. Thailand attracts patients due to its advanced medical facilities, affordable treatments, and regulations that permit comprehensive fertility services.

Capitalizing on this opportunity, First Fertility has developed specialized services to meet the specific cultural and medical needs of Indian patients. The center now includes a dedicated Indian hospitality lounge with culturally relevant amenities, Hindi-speaking customer service and medical consultation teams, and comprehensive fertility treatments, including family balancing through IVF, which is legal in Thailand but restricted in India. These customized services aim to provide a comfortable and culturally sensitive environment while offering access to advanced reproductive technologies that may be limited in patients’ home countries.

Thailand’s advantages as a medical tourism destination continue to fuel sector growth, supported by its advanced healthcare infrastructure, progressive regulatory environment, and supportive tourism policies, such as visa-free entry for Indian nationals. First Fertility is taking advantage of these national benefits while filling a gap in culturally tailored fertility care for Indian patients, a significant and underserved segment in the regional medical tourism market.

Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, stated, “This strategic move is a natural progression of our dedication to providing world-class fertility care while leveraging significant market opportunities in Southeast Asia. Thailand’s progressive regulatory environment, combined with our subsidiary’s expertise in fertility treatments and our new India-focused services, positions us well to meet the increasing demand from Indian medical tourists seeking advanced reproductive care in a culturally welcoming environment.”

About NewGen
NewGen provides comprehensive fertility services in Asia, assisting couples and individuals in accessing fertility treatments. Committed to helping individuals build families, NewGen focuses on increasing access to infertility treatment and delivering comprehensive fertility services. NewGen’s management team has over a decade of experience in the fertility industry. NewGen’s clinics, located in Thailand, Cambodia, and Kyrgyzstan, offer a full range of services, including infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, where legally permitted. For more information, visit . The information on NewGen’s website is not part of this press release.

Forward-Looking Statements
This press release includes forward-looking statements made under the U.S. Private Securities Litigation Reform Act of 1995’s “safe harbor” provisions. These statements are generally identified by terms like “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These statements relate to the Company’s future service offerings and business strategy and are based on current expectations and assumptions, making them subject to risks and uncertainties. Various factors could cause actual events to differ materially from these forward-looking statements, including the Company’s ability to deploy its technology, identify and realize business opportunities, increase market share, and changes in the regulatory or competitive environment. Readers should carefully consider these factors and the risks and uncertainties described in the Company’s annual report on Form 20-F and other filings with the SEC, which may cause actual events and results to differ materially from those in the forward-looking statements. These documents are available on the SEC’s website, www.sec.gov. The information provided is current as of the date of this press release, and the Company does not undertake to update any forward-looking statement, except as required by law.

Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: